Transcriptome analysis of C1q treated lung fibroblasts

Pulmonary fibrosis (PF) is a progressive fibrotic disease with a poor prognosis and suboptimal therapeutic options. The complement molecule C1q, which plays an important role in the phagocytic capacity of macrophages, has recently been reported to exacerbate several fibrosis-related diseases. On the other hand, there are still no reports in PF. Here, we analyzed the effect of C1q treatment on lung fibroblasts. To clarify transcriptomic landscape of C1q treated lung fibroblasts, we purified lineage (CD45, CD31, EpCAM, CD146, and Ter119)– lung fibroblasts by AutoMACS separator from WT mice. Cultured fibroblasts stimulated with C1q (1, 10, and 100 µg/ml, MilliporeSigma) for 2, 24, 48, and 72h and performed transcriptome analysis by 5′sequence using Illumina Novaseq 6000 sequencer.